Intellia Therapeutics Inc. (NTLA)
Intellia Therapeutics: It May Be Time To Get Excited And Buy (Upgrade)
Intellia Therapeutics, Inc.'s lead gene-editing therapies, Lonvo-z and Nex-z, show best-in-class potential with 'one and done' treatment and strong early efficacy and safety data. Recent safety concerns in ATTR-CM seemed to be resolved quickly, and robust patient demand in pivotal trials support confidence in upcoming Phase 3 data and commercial launches. Cash runway extends into late 2026, but pivotal 2025 catalysts and potential blockbuster approval in multi-billion dollar markets could drive significant upside.
Intellia Q2 Loss Narrower Than Expected, Pipeline Progress in Focus
NTLA posts narrower Q2 loss and beats on revenues, while advancing phase III studies for ATTR and HAE programs.
Intellia Therapeutics, Inc. (NTLA) Q2 2025 Earnings Call Transcript
Intellia Therapeutics, Inc. (NASDAQ:NTLA ) Q2 2025 Earnings Conference Call August 7, 2025 8:00 AM ET Company Participants Brittany Chaves - Corporate Participant David Lebwohl - Executive VP & Chief Medical Officer Edward J. Dulac - Executive Vice President, Chief Financial Officer and Treasurer John M.
Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Beats Revenue Estimates
Intellia Therapeutics, Inc. (NTLA) came out with a quarterly loss of $0.99 per share versus the Zacks Consensus Estimate of a loss of $1.03. This compares to a loss of $1.31 per share a year ago.
With Intellia Therapeutics, Human Patience Beat Hot-Take Trading: Still At 'Buy'
Investors often react fast to news. We see it with earnings announcements. And in biotech/pharma, we see it in response to news about drug trials. We saw that in spades on 5/29/25 for gene editor Intellia Therapeutics. The stock lost 29% after news of a “safety concern” surfaced during a Phase III drug trial. The news looked terrible. A lab test showed indications that a patient was experiencing an emergency liver problem. But the asymptomatic condition quickly corrected on its own.
NTLA Stock Down as Patient Faces Adverse Event in Gene Therapy Study
Intellia stock tanks after a patient in its phase III study evaluating gene therapy candidate nex-z in ATTR-CM experiences serious liver enzyme elevation.
Analysts Think These Stocks Could More Than Double in Value
Persistent volatility has plagued the S&P 500 for much of 2025, prompting widespread caution among many investors amid the uncertainties of trade battles, tariffs, domestic policy, and more. Investors might remember that many of the biggest rallies take place during these volatile periods, and there may be potential to win big gains for those with at least a moderate tolerance for risk.
3 Top Genomics Stocks to Add to Your Portfolio in 2025
Investors interested in the Genomics and Synthetic Biology theme may consider adding these three stocks to their portfolio - Intellia Therapeutics (NTLA), uniQure (QURE) and Verve Therapeutics (VERV).
Wall Street Analysts See a 408.63% Upside in Intellia Therapeutics (NTLA): Can the Stock Really Move This High?
The mean of analysts' price targets for Intellia Therapeutics (NTLA) points to a 408.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Intellia Therapeutics, Inc. (NTLA) BofA Securities 2025 Healthcare Conference (Transcript)
Intellia Therapeutics, Inc. (NASDAQ:NTLA ) BofA Securities 2025 Healthcare Conference May 13, 2025 7:20 PM ET Company Participants Ed Dulac - CFO Conference Call Participants Alec Stranahan - BofA Securities Alec Stranahan Hello, everyone. Thanks for joining the session with Intellia Therapeutics on day 1 of the 2025 Bank of America Healthcare Conference.
Intellia Therapeutics Shares Have Struggled, But It's Now Go-Time (Rating Upgrade)
Investors who've been looking for problems at Intellia Therapeutics have, during the past year, had an easy time finding them. A tendency to misinterpret helped. Investors complained about test results that were fine with medical experts and the FDA. The Street hated when NTLA dropped a lesser program and laid off some staff members. On 5/8/25, the Company reported further progress with two treatments that are now ensconced in Phase III of testing—a level only a third of new drugs reach.
Intellia's Q1 Loss Narrower Than Expected, Pipeline in Focus, Stock Up
NTLA reports better-than-expected first-quarter 2025 results. The company provides updates on its pipeline candidates.
